Biodesix (NASDAQ: BDSX) regains compliance with Nasdaq minimum bid price rule

Rhea-AI Filing Summary

Biodesix, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Global Market. On September 26, 2025, Nasdaq notified the company that its common stock once again meets the rule that requires a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. This notice closes the earlier deficiency matter that began when the stock traded below $1.00 for 30 consecutive business days.

Insights

Equity markets analyst

Biodesix has removed an active Nasdaq delisting risk by regaining minimum bid price compliance.

Biodesix received confirmation from Nasdaq on September 26, 2025 that it now complies with the exchange’s minimum bid price rule, which requires its common stock to close at or above $1.00 per share for at least ten consecutive business days. This directly addresses the earlier notice from March 24, 2025, when the shares had closed below $1.00 for 30 straight business days.

This development removes the immediate risk that the stock could be delisted from The Nasdaq Global Market for bid-price noncompliance. Maintaining a Nasdaq Global Market listing can matter for liquidity and for some institutions that are restricted from holding non-listed securities, although this filing does not quantify those effects. Subsequent company filings may provide more context on how management plans to maintain compliance going forward.

BIODESIX INC false 0001439725 0001439725 2025-09-26 2025-09-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

September 26, 2025

Date of Report (Date of earliest event reported)

Biodesix, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39659		20-3986492
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

919 West Dillon Rd.
Louisville, CO		80027
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (303) 417-0500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		BDSX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 26, 2025, Biodesix, Inc., a Delaware corporation (the “Company”) received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Global Market.

As previously disclosed, on March 24, 2025, the Company received a letter from Nasdaq, notifying the Company that it was not in compliance with the Minimum Bid Price Requirement because the Company’s common stock, par value $0.001 (the “Common Stock”), had closed below the $1.00 per share minimum for 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, the Common Stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.

In its letter dated September 26, 2025, Nasdaq indicated the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 1, 2025				BIODESIX, INC.
				By:		/s/ Robin Harper Cowie
				Name:		Robin Harper Cowie
				Title:		Chief Financial Officer

FAQ

What did Biodesix (BDSX) announce in this 8-K filing?

Biodesix disclosed that Nasdaq notified the company on September 26, 2025 that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

Why was Biodesix (BDSX) previously out of compliance with Nasdaq rules?

On March 24, 2025, Biodesix received a notice from Nasdaq stating it was not in compliance because its common stock had closed below $1.00 per share for 30 consecutive business days.

What is Nasdaq’s minimum bid price requirement mentioned for Biodesix (BDSX)?

Nasdaq Listing Rule 5450(a)(1) requires that a company’s common stock maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days to satisfy the minimum bid price requirement.

How did Biodesix (BDSX) regain compliance with the minimum bid price rule?

Biodesix regained compliance after its common stock met Nasdaq’s rule by maintaining a closing bid price of at least $1.00 per share for at least ten consecutive business days, as confirmed in Nasdaq’s September 26, 2025 letter.

What is the status of the prior Nasdaq deficiency notice for Biodesix (BDSX)?

Nasdaq’s letter dated September 26, 2025 stated that Biodesix has regained compliance with the Minimum Bid Price Requirement and that the matter is now closed.

Which market does Biodesix (BDSX) common stock trade on after regaining compliance?

Biodesix’s common stock, par value $0.001 per share, continues to be listed on The Nasdaq Global Market under the trading symbol BDSX.